Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126438 · ClinicalTrials.gov registry record · Phase 3
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 515
- Enrollment target
NCT00126438 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 515 participants.
The verdict
NCT00126438, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 515 participants
- Enrollment target
Study Summary
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
Interventions
- DRUG 123I-mIBG (meta-iodobenzylguanidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126438
The ClinicalTrials.gov registry entry for NCT00126438 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 515 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 123I-mIBG (meta-iodobenzylguanidine) is the first listed.
NCT00126438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126438 about?
NCT00126438 is a clinical study titled "Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease". The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
What is the current status of trial NCT00126438?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 515 participants. The study started on 2005-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00126438?
The interventions under investigation include: 123I-mIBG (meta-iodobenzylguanidine) (DRUG).
Who is sponsoring clinical trial NCT00126438?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.